These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10731271)

  • 1. Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.
    Kereiakes DJ; Broderick TM; Abbottsmith C; Shimshak TM
    J Invasive Cardiol; 2000 Feb; 12(2):95-8. PubMed ID: 10731271
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
    Cote AV; Berger PB; Holmes DR; Scott CG; Bell MR
    Mayo Clin Proc; 2001 Sep; 76(9):890-6. PubMed ID: 11560299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular complications after percutaneous coronary interventions using abciximab (Reopro ): prospective evaluation with Doppler color flow imaging.
    Kranjec I; Cerne A
    J Invasive Cardiol; 2000 Feb; 12(2):86-94. PubMed ID: 10731270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Readministration of abciximab in percutaneous coronary intervention.
    Fry ET
    J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.
    Patel SS; Rana H; Mascarenhas DA
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):89-93. PubMed ID: 18413897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions.
    Best PJ; Lennon R; Gersh BJ; Ting HH; Rihal CS; Bell MR; Herzog CA; Holmes DR; Berger PB
    Am Heart J; 2003 Aug; 146(2):345-50. PubMed ID: 12891206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab in percutaneous coronary intervention in a teaching hospital setting?
    Khan JM; Watson RD; Varma C; Millane T; Lip GY
    Int J Clin Pract; 2006 Apr; 60(4):498-9. PubMed ID: 16620368
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.
    Assali AR; Sdringola S; Moustapha A; Ghani M; Salloum J; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):1-5. PubMed ID: 12508187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-procedural patient management: prevention and management of bleeding complications.
    Aguirre F
    J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
    [No Abstract]   [Full Text] [Related]  

  • 12. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Blankenship JC; Hellkamp AS; Aguirre FV; Demko SL; Topol EJ; Califf RM
    Am J Cardiol; 1998 Jan; 81(1):36-40. PubMed ID: 9462603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.
    Razakjr OA; Tan HC; Yip WL; Lim YT
    J Interv Cardiol; 2005 Feb; 18(1):33-7. PubMed ID: 15788052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gastrointestinal bleeding in a patient with acute myocardial infarction treated with primary coronary angioplasty and abciximab (ReoPro) administration].
    Gziut AI; Pastwa Ł; Słysz A
    Kardiol Pol; 2006 Mar; 64(3):334-6; discussion 337-8. PubMed ID: 16583343
    [No Abstract]   [Full Text] [Related]  

  • 19. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry.
    Siudak Z; Zawislak B; Dziewierz A; Rakowski T; Jakala J; Bartus S; Noworolnik B; Zasada W; Dubiel JS; Dudek D
    Coron Artery Dis; 2010 Aug; 21(5):292-7. PubMed ID: 20453640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.